Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1982;66:29-32

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cade, J. F.
Right arrow Articles by Rennie, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cade, J. F.
Right arrow Articles by Rennie, G. C.

Circulation, Vol 66, 29-32, Copyright © 1982 by American Heart Association


ARTICLES

Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone

JF Cade, DJ Doyle, CN Chesterman, FJ Morgan and GC Rennie

Platelet survival and plasma concentrations of beta thromboglobulin and platelet factor 4 were measured in 44 patients before and 6 months after coronary artery bypass grafting. Postoperatively, patients were randomized to receive sulfinpyrazone, 800 mg/day, or placebo. Preoperatively, platelet survival was significantly shorter than normal, and plasma concentrations of both platelet-specific proteins were significantly elevated. Postoperatively, all three indexes of platelet function tended to become normal, but these changes were statistically significant only in patients treated with sulfinpyrazone. Postoperative exercise testing correlated significantly with plasma concentrations of beta thromboglobulin and platelet factor 4 measured preoperative and postoperative. These results are consistent with reports of the effects of sulfinpyrazine on platelet involvement in other conditions, and suggest that the drug reduces platelet activation and inhibits actual destruction. The results also show a relationship between abnormalities of platelet function and an index of postoperative myocardial ischemia.


This article has been cited by other articles:


Home page
Clin Nurs ResHome page
D. Lamarche, R. Taddeo, and C. Pepler
The Preparation of Patients for Cardiac Surgery
Clin Nurs Res, November 1, 1998; 7(4): 390 - 405.
[Abstract] [PDF]


Home page
BMJHome page
Antiplatelet Trialists
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
BMJ, January 8, 1994; 308(6921): 81 - 106.
[Abstract] [Full Text]


Home page
Eval Health ProfHome page
J. L. Franklin, J. Simmons, B. Solovitz, J. R. Clemons, and G. E. Miller
Assessing Quality of Life of the Mentally Ill: A Three-Dimensional Model
Eval Health Prof, September 1, 1986; 9(3): 376 - 388.
[Abstract] [PDF]